Recent discussions on X about Viking Therapeutics (VKTX) have been buzzing with activity following the company's announcement of the initiation of Phase 3 clinical trials for their drug candidate VK2735, aimed at treating obesity. Many users on the platform have expressed optimism about the potential of this dual GLP-1/GIP agonist, especially given its innovative approach with both injectable and oral forms under development. The news of the VANQUISH Phase 3 program, involving thousands of participants, has sparked conversations about the company's competitive positioning in the rapidly growing weight loss drug market.
While enthusiasm dominates much of the dialogue, there are also notes of caution among some participants on X, with a few highlighting the stock's volatility and past fluctuations despite earlier positive trial data. Discussions often compare Viking's progress to larger pharmaceutical giants, with some suggesting that VK2735 could emerge as a significant contender if the trials succeed. The mix of hope and tempered expectations reflects the high stakes surrounding this biopharmaceutical stock as it navigates critical stages of development.
Note: This discussion summary was generated from an AI condensation of post data.
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 7 times in the past 6 months. Of those trades, 1 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- BRIAN LIAN (President & CEO) has made 0 purchases and 2 sales selling 194,490 shares for an estimated $8,313,601.
- MARIANNA MANCINI (Chief Operating Officer) has made 0 purchases and 2 sales selling 54,215 shares for an estimated $2,317,599.
- GREG ZANTE (Chief Financial Officer) has made 0 purchases and 2 sales selling 50,309 shares for an estimated $2,150,594.
- SARAH KATHRYN ROUAN purchased 1,240 shares for an estimated $29,942
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Viking Therapeutics Hedge Fund Activity
We have seen 219 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 271 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 5,466,101 shares (-32.7%) from their portfolio in Q1 2025, for an estimated $132,006,339
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,357,241 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $32,777,370
- PERPETUAL LTD removed 1,269,152 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $51,070,676
- NORGES BANK added 1,096,559 shares (+601.3%) to their portfolio in Q4 2024, for an estimated $44,125,534
- JPMORGAN CHASE & CO added 968,959 shares (+44.9%) to their portfolio in Q1 2025, for an estimated $23,400,359
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 930,370 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $37,438,088
- STATE STREET CORP removed 870,072 shares (-17.7%) from their portfolio in Q1 2025, for an estimated $21,012,238
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Viking Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $VKTX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 06/25/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/28/2025
- Morgan Stanley issued a "Overweight" rating on 03/12/2025
To track analyst ratings and price targets for Viking Therapeutics, check out Quiver Quantitative's $VKTX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
